KR840005664A - Biospecific Polymer - Google Patents

Biospecific Polymer Download PDF

Info

Publication number
KR840005664A
KR840005664A KR1019830003739A KR830003739A KR840005664A KR 840005664 A KR840005664 A KR 840005664A KR 1019830003739 A KR1019830003739 A KR 1019830003739A KR 830003739 A KR830003739 A KR 830003739A KR 840005664 A KR840005664 A KR 840005664A
Authority
KR
South Korea
Prior art keywords
polymer
bioselective
support
patient
biocompatible polymer
Prior art date
Application number
KR1019830003739A
Other languages
Korean (ko)
Other versions
KR880001097B1 (en
Inventor
디이 쟈리트 로버어트
디이 쟈리트 로버어트 (외 1)
하우워어드 맥케인 지이
Original Assignee
다이아몬드 샴락크 코오포레이션
다인 엘 휴지스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이아몬드 샴락크 코오포레이션, 다인 엘 휴지스 filed Critical 다이아몬드 샴락크 코오포레이션
Publication of KR840005664A publication Critical patent/KR840005664A/en
Application granted granted Critical
Publication of KR880001097B1 publication Critical patent/KR880001097B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Materials Engineering (AREA)
  • Analytical Chemistry (AREA)

Abstract

내용 없음No content

Description

생체선택성 중합체(Biospecific Polymer)Biospecific Polymer

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (20)

생체 양립성 중합체 지지물과 이 지지물에 대한 화학적으로 결합하여 고정되어 있는 하나 또는 몇개의 생화학 물질로 구성되어 있고, 상기 생화학 물질은 특정의 병리요인 또는 특정집단의 병리요인을 결속시키기 위한 반응성을 지니고 있는 것을 특징으로 하는 생체 선택성 중합체.Consisting of a biocompatible polymer support and one or several biochemicals that are fixed in chemical bonds to the support, wherein the biochemicals are reactive to bind a specific pathology or group of pathologies. A bioselective polymer characterized by the above. 생체 양립성 중합체 지지물, 상기 지지물에 공유결합된 간격자, 그리고 상기 간격자에 화학결합으로 고정된 한개 또는 몇개의 생화학물질로 구성되어 있고, 상기 생화학 물질은 특정의 병리요인 또는 특정 집단의 병리요인을 결속시키기 위한 반응성을 지니고 있는 것을 특징으로 하는 생체 선택성 중합체.It consists of a biocompatible polymer support, a spacer covalently bonded to the support, and one or several biochemicals immobilized by a chemical bond to the spacer, wherein the biochemical is capable of identifying a specific pathology or a specific group of pathogens. A bioselective polymer having reactivity for binding. 제1항 또는 제2항에 있어서, 상기 생체 양립성 중합체 지지물이 하이드로겔인 생체 선택성 중합체.The bioselective polymer of claim 1 or 2, wherein the biocompatible polymer support is a hydrogel. 제1항 또는 제2항에 있어서, 상기 생체 양립성 중합체 지지물이 약간 교차결합된 동종중합체 하이드록시 에틸 메타크릴레이트인 생체 선택성 중합체.3. The bioselective polymer of claim 1 or 2, wherein the biocompatible polymer support is a slightly crosslinked homopolymer hydroxy ethyl methacrylate. 제1항 또는 제2항에 있어서, 상기 생체 양립성 중합체 지지물이 중합된 글리시딜 아크릴레이트와 중합된 글리시딜 메타크릴레이트로 구성된 군으로 부터 선택되는 생체 선택성 중합체.3. The bioselective polymer of claim 1 or 2, wherein the biocompatible polymer support is selected from the group consisting of polymerized glycidyl acrylate and polymerized glycidyl methacrylate. 제1항 또는 제2항에 있어서, 상기 생체 양립성 중합체 지지물이 공중합된 N-비닐 피롤리돈 및 글리시딜 메타크릴레이트로 구성된 군으로 부터 선택되고, 또한 상기 공중합체는 하이드록시 알킬아크릴레이트, 하이드록시 알킬메타크릴레이트, 아크릴아미드, 치환 아크릴아미드, 비닐 글리시딜 에테르, 알릴 글리시딜 에테르, N-비닐아미드, 초산비닐 및 이들의 혼합물로 구성된 군으로 부터 선택된 단량체를 포함하는 생체 선택성 중합체.The biocompatible polymer support of claim 1 or 2, wherein the biocompatible polymer support is selected from the group consisting of copolymerized N-vinyl pyrrolidone and glycidyl methacrylate, wherein the copolymer is hydroxy alkylacrylate, Bioselective polymers comprising monomers selected from the group consisting of hydroxy alkylmethacrylates, acrylamides, substituted acrylamides, vinyl glycidyl ethers, allyl glycidyl ethers, N-vinylamides, vinyl acetate and mixtures thereof . 제1항 또는 제2항에 있어서, 상기 중합체 지지물이 글리시딜 메타크릴레이트, N-비닐 피롤리돈 및 하이드록시에틸 메타크릴레이트의 3원 중합체로된 생체 양립성 중합체.The biocompatible polymer according to claim 1 or 2, wherein the polymer support is a tertiary polymer of glycidyl methacrylate, N-vinyl pyrrolidone and hydroxyethyl methacrylate. 제1항 또는 제2항에 있어서, 상기 중합체 지지물이 변형된 초산셀루로즈인 생체 양립성 중합체.The biocompatible polymer according to claim 1 or 2, wherein the polymer support is modified cellulose acetate. 제1항 또는 제2항에 있어서, 상기 중합체 지지물이 기계적으로 안정된 지지 부재에 고정되어 있는 것을 특징으로 하는 생체 선택성 중합체.The bioselective polymer according to claim 1 or 2, wherein the polymer support is fixed to a mechanically stable support member. 제9항에 있어서, 상기 기계저그로 안정된 지지부재가 정제된 초산 셀루로즈, 폴리에스테르 섬유, 미세공 폴리올레핀, 면직물, 폴리스티렌, 폴리카아보네이트, 폴리 페닐렌 산화물, 망상 폴리우레탄 및 이들의 결합으로 구성된 군으로 부터 선택되는 생체 선택성 중합체.10. The method according to claim 9, wherein the support member stabilized by the machine jug is purified by cellulose acetate, polyester fiber, microporous polyolefin, cotton fabric, polystyrene, polycarbonate, polyphenylene oxide, reticulated polyurethane, and combinations thereof. Bioselective polymer selected from the group consisting of. 제1항 또는 제2항에 있어서, 상기 생화학 물질이 아세틸 콜린 수용체 단백질, 조직 양립성 항원, 리보핵산, 기초 박막 단백질, 면역 혈구소류 및 하위분류, 척수단백질 수용체, 보완성분, 척수단백질, 호르몬 및 그 수용체 성분, 비타민 및 그 수용체 성분 등으로 구성되는 군으로 부터 선택되는 생체 선택성 중합체.The method according to claim 1 or 2, wherein the biochemical is acetylcholine receptor protein, tissue compatible antigen, ribonucleic acid, basal thin film protein, immune hemoglobin and subclassification, chuck means protein receptor, complement component, chuck means protein, hormone and its A bioselective polymer selected from the group consisting of receptor components, vitamins and their receptor components and the like. 제1항 또는 제2항에 있어서, 상기 생화학 물질이 자가 면역성 질병인 인슐린 저항과 관련된 항-인슐린 항체를 제거하기 위하여 사용되는 인슐린인 것을 특징으로 하는 생체 선택성 중합체.The bioselective polymer according to claim 1 or 2, wherein the biochemical is insulin used to remove anti-insulin antibodies associated with insulin resistance, which is an autoimmune disease. 제1항 또는 제2항에 있어서, 상기 생화학 물질이 류마티스성 관절염 및 암과 같은 결합조직과 증식성 질병에 관련된 면역성분을 제거하기 위하여 정제 감마 혈구소인 것을 특징으로 하는 생체 선택성 중합체.The bioselective polymer according to claim 1 or 2, wherein the biochemical is purified gamma hemoglobin for removing immune components related to connective tissue and proliferative diseases such as rheumatoid arthritis and cancer. 제2항에 있어서, 상기 간격자가 1,6-디아미노헥산, 글루타르알데히드, 1,4-사이클로헥산-디카르복실산, 에틸렌 디아민 테트라초산, 트리에틸렌글리콜, 1,4-부탄디올 디글리시딜에테르, 메틸렌-p-페닐 디이소시아네이트, 6-아미노 카프로인산, p-니트로 벤조일 클로라이드, 1,2-에폭시-3-(p-니트로페녹시)프로판, 아미노 프로필트리에톡시-실란, 석신산 무수물, 호모앞테인 티오락톤 및 알부민 등으로 구성되는 군으로 부터 선택되는 생체 선택성 중합체.The method of claim 2, wherein the spacer is 1,6-diaminohexane, glutaraldehyde, 1,4-cyclohexane-dicarboxylic acid, ethylene diamine tetraacetic acid, triethylene glycol, 1,4-butanediol diglyci Diether, methylene-p-phenyl diisocyanate, 6-amino caproic acid, p-nitro benzoyl chloride, 1,2-epoxy-3- (p-nitrophenoxy) propane, amino propyltriethoxy-silane, succinic acid A bioselective polymer selected from the group consisting of anhydrides, homoacid thiolactones, albumin and the like. 생체 양립성 중합체 지지물과 이 지지물에 고정된 반응성 생화학물질로 구성된 생체 선택성 중합체에 환자의 생체 유동액을 접촉시킴으로써, 상기 생화학 물질이 상기 환자의 질병상태와 관련된 특정의 병리요인 또는 특정 집단의 병리요인을 결속시키게하고, 상기 생체 유동액을 상기 환자에게 재투입하는 것을 특징으로 하는 질병치료법.By contacting a biofluid of a patient with a bioselective polymer consisting of a biocompatible polymer support and a reactive biochemical immobilized to the support, the biochemical can be used to determine a specific pathology or a specific population of pathologies associated with the disease state of the patient. And binding said biofluid to said patient. 생체 양립성 중합체 지지물, 이 지지물에 부착된 간격자, 그리고 이 간격자에 고정된 생화학 물질로 구성된 생체 선택성 중합체에 환자의 생체 유동액을 접촉시킴으로써, 상기 생화학 물질이 상기 환자의 질병상태와 관련된 특정의 병리요인 또는 특정집단의 병리요인을 결속시키게 하고, 상기 생체 유동액을 상기 환자에게 재투입하는 것을 특징으로 하는 질병 치료법.By contacting a biofluid of a patient with a bioselective polymer consisting of a biocompatible polymer support, a spacer attached to the support, and a biochemical fixed to the spacer, the biochemical can be applied to a specific condition associated with the disease state of the patient. Binding a pathology agent or a specific group of pathogens, and re-injecting the biofluid into the patient. 환자에게 투여할 생체 유동액을 상기 환자에게 투여하기 이전에, 생체 양립성 중합체 지지물 및 이에 고정된 방응성 생화학 물질로 된 생체 선택성 중합체와 접촉시킴으로써, 상기 생체 유동액으로 부터 특정의 병리요인을 제거하고, 다음에 상기 생체 유동액을 상기 환자에게 투입하는 것을 특징으로 하는 질병치료법.Prior to administering to the patient a biofluid to be administered to the patient, specific pathogens are removed from the biofluid by contacting the biocompatible polymer support and the bioselective polymer immobilized thereon. And then injecting the biological fluid into the patient. 환자에게 투여할 생체 유동액을 상기 환자에게 투여하기 이전에, 생체 양립성 중합체 지지물, 이 지지물에 부착된 간격자, 그리고 이 간격자에 고정된 생화학 물질로 구성된 생체 선택성 중합체와 접촉시킴으로써, 상기 생체 유동액으로 부터 특정의 병리용인을 제거하고, 다음에 상기 생체 유동액을 상기 환자에게 투입하는 것을 특징으로 하는 질병치료법.Before administering to the patient a biofluid to be administered to the patient, the biofluid is contacted with a biocompatible polymer comprising a biocompatible polymer support, a spacer attached to the support, and a biochemical fixed to the spacer. Removing certain pathologies from the fluid, and then introducing the biological fluid into the patient. 제15항, 제16항, 제17항 또는 제18항중 어느 한항에 있어서, 2개 또는 그 이상의 생체 선택성 중합체를 차례로 사용하고, 이들 중합체의 각각에는 동일하거나 상이한 반응성 생화학 물질 또는 그 집단이 고정되어 있어서 상기 특정의 병리요인을 제거하는 것을 특징으로 하는 질병치료법.19. The method according to any one of claims 15, 16, 17 or 18, wherein two or more bioselective polymers are used in turn, and each of these polymers is immobilized with the same or different reactive biochemicals or populations thereof. Removing the specific pathogen. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019830003739A 1982-08-12 1983-08-10 Biospecific polymer KR880001097B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40761382A 1982-08-12 1982-08-12
US40761482A 1982-08-12 1982-08-12
US407613 1982-08-12
US407,614 1982-08-12
US407614 1982-08-12
US407,613 1982-08-12

Publications (2)

Publication Number Publication Date
KR840005664A true KR840005664A (en) 1984-11-15
KR880001097B1 KR880001097B1 (en) 1988-06-29

Family

ID=27019939

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830003739A KR880001097B1 (en) 1982-08-12 1983-08-10 Biospecific polymer

Country Status (11)

Country Link
KR (1) KR880001097B1 (en)
AU (1) AU570213B2 (en)
BR (1) BR8304308A (en)
DD (1) DD221367A5 (en)
DK (1) DK366183A (en)
IL (1) IL69468A (en)
IN (1) IN161386B (en)
MX (1) MX7678E (en)
NO (1) NO160968C (en)
PL (1) PL142532B1 (en)
YU (1) YU169183A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595654A (en) * 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US5149788A (en) * 1987-05-19 1992-09-22 Hoffmann-La Roche, Inc. Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography
SE8804164A0 (en) * 1988-11-17 1990-05-18 Per Prisell Pharmaceutical preparation
GB0112363D0 (en) * 2001-05-21 2001-07-11 Allied Therapeutics Ltd Method and apparatus for treating biological fluids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS167530B1 (en) * 1972-03-29 1976-04-29 Jiri Coupek Method of insoluble biologically active compounds preparation
US3826678A (en) * 1972-06-06 1974-07-30 Atomic Energy Commission Method for preparation of biocompatible and biofunctional materials and product thereof
GB2092470B (en) * 1981-02-10 1984-07-18 Tanabe Seiyaku Co Method for reducing the pyrogen content of or removing pyrogens from solutions contaminated therewith

Also Published As

Publication number Publication date
DK366183D0 (en) 1983-08-11
IL69468A (en) 1986-12-31
DK366183A (en) 1984-02-13
MX7678E (en) 1990-08-07
PL142532B1 (en) 1987-10-31
AU1796583A (en) 1984-02-23
IN161386B (en) 1987-11-21
YU169183A (en) 1986-04-30
IL69468A0 (en) 1983-11-30
DD221367A5 (en) 1985-04-24
NO832889L (en) 1984-02-13
AU570213B2 (en) 1988-03-10
BR8304308A (en) 1984-03-20
PL243388A1 (en) 1985-08-13
KR880001097B1 (en) 1988-06-29
NO160968B (en) 1989-03-13
NO160968C (en) 1989-06-28

Similar Documents

Publication Publication Date Title
AU628674B2 (en) Polymer complexes of a sugar response type
EP0374182B1 (en) Biospecific polymers
US4687808A (en) Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors
DE69632731D1 (en) BLOOD COLLECTION AND SEPARATION SYSTEM
RU94040717A (en) Implanted device
FR2616437B1 (en) COMPOSITE POLYMERS, THEIR PREPARATION AND THEIR USE IN LIQUID CHROMATOGRAPHY
EP2126582A2 (en) Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis
ATE198492T1 (en) GENE THERAPY OF DISEASES CAUSED BY THE IMMUNE SYSTEM USING A CELL-SPECIFIC CELL CYCLE-REGULATED ACTIVE SUBSTANCE
CA2295604A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Issitt et al. Autoantibodies mimicking alloantibodies
Phillips Analytical techniques in immunochemistry
KR840005664A (en) Biospecific Polymer
EP0103184B1 (en) Activation of biocompatible terpolymers with biologicals whose binding complements are pathological effectors
KR850000960A (en) Treatment device to treat disease in vitro
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
JP3087293B2 (en) Sugar-responsive polymer complex
JPH0245064A (en) Device for removing interleukin 2 receptor and blood extra-corporeal circulating device provided with this device
JPH0558707B2 (en)
JP2000086534A (en) Sugar-responding polymer complex
Gunby Viral infection may lead to vessel wall problems
CA1217424A (en) Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors
RU95107294A (en) Method and device for performing membrane plasmapheresis according to single needle mode using gravity
Henry et al. A “Normal” Individual with a Positive Direct Antiglobulin Test Case Complicated by Pregnancy and Unusual Autoantibody Specificity
JPS5949773A (en) Activation of biologically compatible polymer by biological drug using phatological operating body as binding compliance
Chow et al. Antibody against compound antigen ce (f)

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee